As filed with the Securities and Exchange Commission on February 25, 2025

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Kiniksa Pharmaceuticals International, plc 

(Exact name of registrant as specified in its charter)

England and Wales	98-1795578
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

23 Old Bond Street, Floor 3

London, W1S 4PZ

England, United Kingdom

(Address of Principal Executive Offices) (Zip Code)

Kiniksa Pharmaceuticals International, plc 2018 Incentive Award Plan
Kiniksa Pharmaceuticals International, plc 2018 Employee Share Purchase Plan 

(Full title of the plan)

Kiniksa Pharmaceuticals Corp. 

100 Hayden Avenue 

Lexington, MA 02421 

(Name and address for agent for service)

(781) 431-9100 

(Telephone number, including area code, of agent for service)

Copies to:

Paul M. Kinsella 

Marko S. Zatylny 

Ropes & Gray LLP 

Prudential Tower 

800 Boylston Street 

Boston, Massachusetts 02199 

(617) 951-7000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨	Smaller reporting company	¨
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

PART I

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,900,642 Class A ordinary shares, nominal value $0.000273235 per share (“Class A ordinary shares”) of Kiniksa Pharmaceuticals International, plc (the “Registrant”) to be issued pursuant to the Registrant’s 2018 Incentive Award Plan (the “2018 Plan”) and an additional 90,000 Class A ordinary shares of the Registrant to be issued pursuant to the Registrant’s 2018 Employee Share Purchase Plan (the “2018 ESPP”). Registration Statements of the Registrant on Forms S-8 relating to the same employee benefit plans are effective.

INCORPORATION BY REFERENCE OF CONTENTS OF

REGISTRATION STATEMENTS ON FORM S-8

Except as set forth below, the contents of the Registration Statements on Form S-8 (Reg. Nos. 333-277480, 333-270226, 333-262971, 333-253514, 333-237589, 333-225196) filed with the Securities and Exchange Commission (the “Commission”) relating to the 2018 Plan and the 2018 ESPP, each as amended by a post-effective amendment number one, filed with the Commission on June 28, 2024, are incorporated by reference herein.

PART II

INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 8. Exhibits.

		Incorporated by Reference
Exhibit Number	Exhibit Description	Form	File No.	Exhibit	Filing Date	Filed Herewith
4.1	Articles of Association of Kiniksa Pharmaceuticals International, plc	8-K12B	001-38492	3.1	6/28/2024
4.2	Specimen Share Certificate evidencing the Class A Ordinary Shares	8-K12B	001-38492	4.1	6/28/2024
5.1	Opinion of Ropes & Gray LLP, counsel to the Registrant					*
23.1	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm					*
23.2	Consent of Ropes & Gray LLP (included in Exhibit 5.1)					*
24.1	Power of attorney (included on signature pages below)					*
99.1	2018 Incentive Award Plan and forms of award agreements thereunder	8-K12B	001-38492	10.4	6/28/2024
99.2	2018 Incentive Award Plan; Subplan for UK Employees and forms of award agreements thereunder	8-K12B	001-38492	10.5	6/28/2024
99.3	2018 Incentive Award Plan; Forms of option grant notice and option agreement for German participants, restricted share grant notice and restricted share agreement for German participants, and restricted share unit grant notice and restricted share unit agreement for German participants	8-K12B	001-38492	10.6	6/28/2024
99.4	2018 Incentive Award Plan forms of option grant notice and option agreement for Swiss participants, restricted share grant notice and restricted share agreement for Swiss participants, and restricted share unit grant notice and restricted share unit agreement for Swiss participants	8-K12B	001-38492	10.7	6/282024
99.5	Form of 2024 Performance Share Unit Grant Notice and 2024 Performance Share Unit Award Agreement	10-Q	001-38492	10.2	4/25/2024
99.6	2018 Employee Share Purchase Plan	8-K12B	001-38492	10.8	6/28/2024
107	Filing Fee Table.					*

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on this 25th day of February 2025.

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
By:	/s/ Sanj K. Patel
	Sanj K. Patel
	Chief Executive Officer and Chairman of the Board

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sanj K. Patel and Mark Ragosa, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE
/s/ Sanj K. Patel	Chief Executive Officer and Chairman of the Board	February 25, 2025
Sanj K. Patel	(principal executive officer)
/s/ Mark Ragosa	SVP, Chief Financial Officer	February 25, 2025
Mark Ragosa	(principal financial officer)
/s/ Michael R. Megna	Group VP, Finance and Chief Accounting Officer	February 25, 2025
Michael R. Megna	(principal accounting officer)
/s/ Felix J. Baker	Lead Independent Director	February 25, 2025
Felix J. Baker
/s/ Stephen R. Biggar	Director	February 25, 2025
Stephen R. Biggar
/s/ M. Cantey Boyd	Director	February 25, 2025
M. Cantey Boyd
/s/ G. Bradley Cole	Director	February 25, 2025
G. Bradley Cole
/s/ Richard S. Levy	Director	February 25, 2025
Richard S. Levy
/s/ Thomas R. Malley	Director	February 25, 2025
Thomas R. Malley
/s/ Tracey L. McCain	Director	February 25, 2025
Tracey L. McCain
/s/ Kimberly J. Popovits	Director	February 25, 2025
Kimberly J. Popovits
/s/ Barry D. Quart	Director	February 25, 2025
Barry D. Quart

U.S. AUTHORIZED REPRESENTATIVE

Pursuant to the requirements of the Securities Act of 1933, as amended, the duly authorized representative in the United States of the Registrant has signed this registration statement, on this 25th day of February 2025.

KINIKSA PHARMACEUTICALS CORP.
By:	/s/ Sanj K. Patel
	Sanj K. Patel
	Chief Executive Officer